Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.
BACKGROUND
KIT tyrosine kinase inhibitors (TKI), such as nilotinib or midostaurin (PKC412), are increasingly used in clinical trials to counteract neoplastic cell growth in patients with aggressive mast cell (MC) disorders. However, these patients suffer not only from MC infiltration and consecutive organ damage but also from MC mediator-related symptoms.


METHODS
We examined the effects of three KIT TKI, imatinib, nilotinib, and midostaurin, on IgE-dependent mediator release in normal human blood basophils and cultured cord blood cell-derived MC, and on spontaneous histamine secretion in the MC leukaemia cell line HMC-1 and the basophil cell line KU812.


RESULTS
The multi-kinase inhibitor midostaurin that interacts with KIT and protein kinase C was found to counteract anti-IgE-induced mediator release in blood basophils and cultured cord blood cell-derived MC in all samples examined. By contrast, no effects of imatinib or nilotinib on histamine secretion in basophils or MC were found. The effects of midostaurin on histamine release were dose-dependent and occurred at pharmacologic concentrations (IC(50) 10-100 nm). Midostaurin was also found to inhibit the IgE-dependent up-regulation of CD63 on cultured cord blood cell-derived human MC, but did not inhibit IgE-dependent up-regulation of CD63 or CD203c in human blood basophils.


CONCLUSIONS
Midostaurin may be a beneficial drug in aggressive systemic mastocytosis not only because of its growth-inhibitory effects but also because of its additional effects on activation and mediator release in MC and basophils.
Krauth
M-T
MT
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Mirkina
I
I
Herrmann
H
H
Baumgartner
C
C
Kneidinger
M
M
Valent
P
P
D015703:Antigens, CD / Q000096:biosynthesis; D001491:Basophils / Q000378:metabolism*; D002460:Cell Line; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism / Q000494:pharmacology*; D018836:Inflammation Mediators / Q000378:metabolism*; D008407:Mast Cells / Q000378:metabolism*; D034721:Mastocytosis, Systemic / Q000188:drug therapy / Q000378:metabolism; D010727:Phosphoric Diester Hydrolases / Q000096:biosynthesis; D010980:Platelet Membrane Glycoproteins / Q000096:biosynthesis; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors / Q000378:metabolism; D011755:Pyrophosphatases / Q000096:biosynthesis; D019311:Staurosporine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D060149:Tetraspanin 30; D015854:Up-Regulation / Q000187:drug effects
D015703:Antigens, CD; C554586:CD63 protein, human; C427944:ENPP3 protein, human; D004791:Enzyme Inhibitors; D018836:Inflammation Mediators; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30; D007073:Immunoglobulin E; D019009:Proto-Oncogene Proteins c-kit; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases; D019311:Staurosporine; C059539:midostaurin